| 321 |
SUBCLINICAL RENAL AFFECTION IN PATIENTS WITH Β-THALASSEMIA MAJOR: IN RELATION TO CHELATION THERAPY VERSUS BLOOD TRANSFUSION THERAPY. |
2015 |
| 322 |
SUBCLINICAL RENAL AFFECTION IN PATIENTS WITH Β-THALASSEMIA MAJOR: IN RELATION TO CHELATION THERAPY VERSUS BLOOD TRANSFUSION THERAPY. |
2015 |
| 323 |
SUBCLINICAL RENAL AFFECTION IN PATIENTS WITH Β-THALASSEMIA MAJOR: IN RELATION TO CHELATION THERAPY VERSUS BLOOD TRANSFUSION THERAPY. |
2015 |
| 324 |
SUBCLINICAL RENAL AFFECTION IN PATIENTS WITH Β-THALASSEMIA MAJOR: IN RELATION TO CHELATION THERAPY VERSUS BLOOD TRANSFUSION THERAPY. |
2015 |
| 325 |
The Impact of Different TP53 Mutations on Outcome in Patients with Myelodysplastic Syndromes (MDS) |
2015 |
| 326 |
Deferasirox versus Deferoxiamine for the Treatment of Transfusional Iron Overload in Patients with β-Thalassemia Major
|
2014 |
| 327 |
Deferasirox versus Deferoxiamine for the Treatment of Transfusional Iron Overload in Patients with β-Thalassemia Major
|
2014 |
| 328 |
Pulse Cyclophosphamide Therapy in Refractory Warm Autoimmune Hemolytic Anemia: A New Perspective
|
2014 |
| 329 |
Pulse Cyclophosphamide Therapy in Refractory Warm Autoimmune Hemolytic Anemia: A New Perspective
|
2014 |
| 330 |
Aetiologic mechanisms of dysphagia in lung cancer:
A case series |
2014 |
هل لديك سؤال ؟
